Madrigal Pharmaceuticals, Inc. - Common Stock — Bilan (NASDAQ:MDGL) | MetaTrader

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Total de l'actif 287 M273.33 M362.57 M640.55 M1.04 B1.26 B Total du passif 47.02 M77.22 M165.18 M235.21 M287.86 M656.9 M Total des capitaux propres 239.97 M196.11 M197.39 M405.33 M754.38 M602.69 M Total du passif et des capitaux propres 287 M273.33 M362.57 M640.55 M1.04 B1.26 B Dette totale ——49.29 M115.48 M117.57 M339.88 M Dette nette ——49.29 M-518.65 M-813.68 M-643.68 M

Nouvelles

Truist relève son objectif de cours sur Madrigal Pharmaceuticals après une enquête sur le MASH

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

Wolfe Research réitère sa note Peerperform sur l’action Madrigal

United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?

Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?